All In Biotech

BLA 761355 · Regeneron Pharmaceuticals

Eylea Hd

Aflibercept · Injection · Vascular Endothelial Growth Factor Inhibitor

Priority review

Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Aug 18, 2023

Approved uses

3

Original approval plus efficacy supplements

Registered trials

474

135 Phase 3, 39 recruiting

FAERS reports

4,671

4,088 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 6, 2026.

EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Diabetic Retinopathy (DR) ( 1.3 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Diabetic Retinopathy (DR) 1.4 Macular Edema Following Retinal Vein Occlusion (RVO)

Mechanism: Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 2, 2026 Supplement 5 · Efficacy LabelLetter
  • Nov 19, 2025 Supplement 10 · Efficacy · priority review LabelLetter
  • Aug 18, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
  • EYLEA HD · AFLIBERCEPT 8MG(0.07ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aflibercept" as an intervention, any sponsor and status, largest first.

All 474 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use506
  • diarrhoea380
  • visual acuity reduced221
  • neutropenia215
  • hypertension210
  • endophthalmitis207
  • visual impairment179
  • vision blurred169
  • asthenia155
  • disease progression154
  • drug ineffective153
  • eye inflammation150

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20075
20082
200911
201045
201127
201257
2013240
2014162
2015159
2016180
2017182
2018532
2019328
2020212
2021200
2022170
2023222
2024505
2025789
2026643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eylea Hd (Aflibercept)

2024 spending

$11.7M

Beneficiaries

1,007

3,538 claims

Per beneficiary

$11,608

$37,465.32 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$656,380
2024$11,688,806

Part B: Eylea Hd (Aflibercept) · HCPCS J0177

2024 spending

$666M

Beneficiaries

66,767

211,930 claims

Per beneficiary

$9,972

2024 ASP limit $337.05 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$665,780,688

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 641 on PubMed

Sponsor: Regeneron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.